Why United Therapeutics (UTHR) Stock Is Up Today

United Therapeutics (UTHR) is up 7.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is a major patent-litigation win against Liquidia that strengthens United Therapeutics’ position in pulmonary hypertension associated with interstitial lung disease. Investors appear to be treating the ruling as a positive signal for the durability of the Tyvaso franchise and for future cash flow tied to that market.

Details:

United Therapeutics said a federal court in Delaware found that Liquidia infringed two claims of United Therapeutics’ patent covering the use of inhaled treprostinil for PH-ILD.

The company said the court also concluded Liquidia failed to prove those claims were invalid, which removes an important overhang around competitive pressure in this indication.

United Therapeutics said it believes the ruling could support an order directing the FDA to withdraw approval of Yutrepia until labeling omitting the PH-ILD indication can be approved.

The move may have been reinforced by shareholder-friendly capital allocation already announced in September, including an accelerated share repurchase tied to the remaining balance of its $2.0 billion authorization.

Sources:

United Therapeutics Investor Relations, United States District Court for the District of Delaware, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$UTHR Insider Trading Activity

$UTHR insiders have traded $UTHR stock on the open market 1511 times in the past 6 months. Of those trades, 0 have been purchases and 1511 have been sales.

Here’s a breakdown of recent trading of $UTHR stock by insiders over the last 6 months:

MARTINE A ROTHBLATT (Chairperson & CEO) has made 0 purchases and 1185 sales selling 1,083,000 shares for an estimated $583,704,051.
JAMES EDGEMOND (CFO AND TREASURER) has made 0 purchases and 224 sales selling 208,750 shares for an estimated $117,467,209.
PAUL A MAHON (EVP & GENERAL COUNSEL) has made 0 purchases and 96 sales selling 91,300 shares for an estimated $49,254,897.
CHRISTOPHER PATUSKY has made 0 purchases and 2 sales selling 3,910 shares for an estimated $2,234,670.
NILDA MESA has made 0 purchases and 3 sales selling 486 shares for an estimated $265,477.
JAN MALCOLM sold 325 shares for an estimated $178,941

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive UTHR Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$UTHR Hedge Fund Activity

We have seen 407 institutional investors add shares of $UTHR stock to their portfolio, and 378 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WELLINGTON MANAGEMENT GROUP LLP removed 885,222 shares (-39.1%) from their portfolio in Q2 2026, for an estimated $479,639,836
VESTAL POINT CAPITAL, LP added 360,000 shares (+480.0%) to their portfolio in Q2 2026, for an estimated $195,058,800
D. E. SHAW & CO., INC. removed 306,971 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $166,326,096
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 297,162 shares (+inf%) to their portfolio in Q2 2026, for an estimated $161,011,286
JANE STREET GROUP, LLC added 283,167 shares (+10263.4%) to their portfolio in Q2 2026, for an estimated $153,428,375
AQR CAPITAL MANAGEMENT LLC removed 280,224 shares (-33.9%) from their portfolio in Q2 2026, for an estimated $151,833,769
JPMORGAN CHASE & CO added 275,358 shares (+inf%) to their portfolio in Q2 2026, for an estimated $149,197,225

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$UTHR Government Contracts

We have seen $1,573,798 of award payments to $UTHR over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

TYVASO KITS & CARTRIDGES: $379,307
PATIENT MEDICATION OF TYVASO 80MG - SHIPPING TO THE BALTIMORE VA MEDICAL CENTER PHARMACY.: $33,158
PATIENT MEDICATION ORDER OF TYVASO 80MG FOR THE BALTIMORE VA MEDICAL CENTER PHARMACY.: $33,158
TYVASO 80 MCG: $33,158

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$UTHR Price Targets

Multiple analysts have issued price targets for $UTHR recently. We have seen 3 analysts offer price targets for $UTHR in the last 6 months, with a median target of $704.0.

Here are some recent targets:

Lisa Walter from RBC Capital set a target price of $704.0 on 07/07/2026
Benjamin Burnett from Wells Fargo set a target price of $738.0 on 05/07/2026
Terence Flynn from Morgan Stanley set a target price of $519.0 on 04/10/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.